Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Romark Laboratories L.c.
Romark Laboratories L.c.
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Alinia
Nitazoxanide
2004-07-21
Diarrhea
,
Giardiasis
,
Cryptosporidiosis
,
Protozoan infections
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Nitazoxanide
liver diseases
,
hepatic insufficiency
,
kidney diseases
,
renal insufficiency
,
retinal diseases
,
liver cirrhosis
,
fibrosis
,
neoplasms
,
hepatitis b
,
chronic hepatitis b
,
coinfection
,
periodontitis
,
viral pneumonia
,
coronavirus
,
non-alcoholic fatty liver disease
,
fatty liver
,
alcoholic fatty liver
,
ulcerative colitis
,
ulcer
,
helminthiasis
,
protozoan infections
,
norovirus
,
tuberculosis
,
bronchiolitis
,
emergencies
,
clostridioides difficile
,
crohn disease
,
constipation
,
diabetes mellitus
,
hiv infections
,
cryptosporidiosis
,
severe acute respiratory syndrome
,
human influenza
,
brain diseases
,
hepatic encephalopathy
,
colitis
,
diarrhea
,
gastroenteritis
,
rotavirus infections
,
malnutrition
,
pneumonia
,
enterovirus
,
rhinovirus
,
enterovirus infections
,
recurrence
,
clostridium infections
,
amebiasis
,
amebic dysentery
,
pseudomembranous enterocolitis
,
enterocolitis
,
growth disorders
,
cognitive science
,
dyspepsia
,
peritonitis
,
virus diseases
,
adenoviridae infections
,
caliciviridae infections
,
sars-cov-2
,
rheumatoid arthritis
,
arthritis
,
sexually transmitted diseases
,
dementia
,
cognitive dysfunction
,
colorectal neoplasms
,
covid-19
,
hepatitis
,
hepatitis a
,
hepatitis c
,
infections
,
chronic hepatitis c
,
communicable diseases
,
chronic hepatitis
,
coronavirus infections
,
helicobacter infections
,
gastritis
,
type 2 diabetes mellitus
,
irritable bowel syndrome
,
syndrome
,
cerebral palsy
,
diet therapy
,
nutrition disorders
,
child nutrition disorders
,
probiotics
,
drug interactions
,
muscle spasticity
,
paralysis
,
microsporidiosis
Benzocaine
drug interactions
,
liver diseases
,
hepatic insufficiency
,
pancreatic neoplasms
,
adenocarcinoma
,
neuroendocrine tumors
,
cachexia
Tenofovir
hepatitis b
,
chronic hepatitis b
,
hepatitis
,
chronic hepatitis
,
hepatitis a
Alfacalcidol
heart failure
,
hypertension
,
hepatitis c
,
hepatitis
,
hepatitis a
,
aspergillosis
,
pulmonary aspergillosis
,
candidemia
,
invasive candidiasis
,
candidiasis
Albinterferon alfa-2b
hepatitis
,
hepatitis a
,
hepatitis c
,
chronic hepatitis c
,
hepatitis b
,
chronic hepatitis b
,
chronic hepatitis
,
melanoma
Retinol
hypercholesterolemia
,
hyperlipidemias
,
vitamin d deficiency
,
familial combined hyperlipidemia
,
hyperlipoproteinemias
,
osteoporosis
,
postmenopausal osteoporosis
Fendrix
hepatitis b
,
chronic hepatitis b
,
hepatitis
,
chronic hepatitis
,
hepatitis a
Fluzone
pulmonary arterial hypertension
,
eisenmenger complex
Flumist
pulmonary arterial hypertension
,
eisenmenger complex
Flucelvax
pulmonary arterial hypertension
,
eisenmenger complex
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use